1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Generics in Turkey

Generics in Turkey

  • January 2016
  • -
  • MarketLine
  • -
  • 30 pages

Introduction

Generics in Turkey industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Turkey generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

- For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

- The Turkish generics market is forecast to generate total revenues of $2.0bn in 2015, representing a compound annual rate of change (CARC) of -2.8% between 2011 and 2015.

- Market consumption volume is forecast to reach a total of 50.5% of total pharma volume in 2015.

- Despite overall decline, Turkey’s domestic generic market is healthy. Domestically produced generic products grew by 7.3% between 2013 and 2014. 65% of the drugs manufactured in Turkey in 2014 were generics.

Features

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Turkey

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Turkey

- Leading company profiles reveal details of key generics market players’ global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the Turkey generics market with five year forecasts by both value and volume

- Macroeconomic indicators provide insight into general trends within the Turkey economy

Key Questions Answered

- What was the size of the Turkey generics market by value in 2015?

- What will be the size of the Turkey generics market in 2020?

- What factors are affecting the strength of competition in the Turkey generics market?

- How has the market performed over the last five years?

- How large is Turkey’s generics market in relation to its regional counterparts?

Table Of Contents

Generics in Turkey
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market volume 9
Market Segmentation 10
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Market volume forecast 12
Five Forces Analysis 13
Summary 13
Buyer power 14
Supplier power 15
New entrants 16
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. 19
DEVA Holding 20
Nobel Pharmaceuticals 23
Sandoz International GmbH 24
Macroeconomic Indicators 25
Country Data 25
Methodology 27
Industry associations 28
Related MarketLine research 28
Appendix 29
About MarketLine 29

List of Tables
Table 1: Turkey generics market value: $ billion, 2011-15(e)
Table 2: Turkey generics market volume: % of total pharma volume, 2011-15(e)
Table 3: Turkey generics market geography segmentation: $ billion, 2015(e)
Table 4: Turkey generics market value forecast: $ billion, 2015-20
Table 5: Turkey generics market volume forecast: % of total pharma volume, 2015-20
Table 6: Abdi Ibrahim Ilac Sanayi ve Ticaret A.S.: key facts
Table 7: DEVA Holding: key facts
Table 8: DEVA Holding: key financials ($)
Table 9: DEVA Holding: key financials (TL)
Table 10: DEVA Holding: key financial ratios
Table 11: Nobel Pharmaceuticals: key facts
Table 12: Sandoz International GmbH: key facts
Table 13: Turkey size of population (million), 2011-15
Table 14: Turkey gdp (constant 2005 prices, $ billion), 2011-15
Table 15: Turkey gdp (current prices, $ billion), 2011-15
Table 16: Turkey inflation, 2011-15
Table 17: Turkey consumer price index (absolute), 2011-15
Table 18: Turkey exchange rate, 2011-15

List of Figures
Figure 1: Turkey generics market value: $ billion, 2011-15(e)
Figure 2: Turkey generics market volume: % of total pharma volume, 2011-15(e)
Figure 3: Turkey generics market geography segmentation: % share, by value, 2015(e)
Figure 4: Turkey generics market value forecast: $ billion, 2015-20
Figure 5: Turkey generics market volume forecast: % of total pharma volume, 2015-20
Figure 6: Forces driving competition in the generics market in Turkey, 2015
Figure 7: Drivers of buyer power in the generics market in Turkey, 2015
Figure 8: Drivers of supplier power in the generics market in Turkey, 2015
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Turkey, 2015
Figure 10: Factors influencing the threat of substitutes in the generics market in Turkey, 2015
Figure 11: Drivers of degree of rivalry in the generics market in Turkey, 2015
Figure 12: DEVA Holding: revenues and profitability
Figure 13: DEVA Holding: assets and liabilities

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.